Patents Assigned to Novartis AG
  • Method of deriving a value for percent biomarker positivity for selected cells present in a field of view
    Patent number: 11480570
    Abstract: The invention relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 25, 2022
    Assignee: NOVARTIS AG
    Inventors: Naveen Dakappagari, Jennifer Bordeaux, Thai Tran, Ju Young Kim
  • Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
    Patent number: 11478480
    Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: October 25, 2022
    Assignee: Novartis AG
    Inventors: Joseph Paul Bullock, Chinmay Maheshwari, Quintus Medley, Muneto Mogi, Michela Montecchi-Palmer, Kalliopi Stasi
  • Compositions and methods for decreasing tau expression
    Patent number: 11473083
    Abstract: Provided herein are compositions and methods for decreasing tau mRNA and protein expression. These compositions and methods are useful in treating tau-related diseases and disorders.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: October 18, 2022
    Assignee: NOVARTIS AG
    Inventors: Manuela Polydoro Ofengeim, Jan Weiler
  • Methods and systems for polymer precipitation and generation of particles
    Patent number: 11464871
    Abstract: Processes for precipitating polymers from a polymer-containing solution are disclosed.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: October 11, 2022
    Assignee: Novartis AG
    Inventor: J. Michael Ramstack
  • 3? end caps, 5? end caps and combinations thereof for therapeutic RNA
    Patent number: 11466048
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: October 11, 2022
    Assignee: NOVARTIS AG
    Inventors: David Barnes-Seeman, Scott Louis Cohen, John Louis Diener, Christian Gampe, James Roache, Amy White, Sarah Louise Williams, Jun Yuan, Frederic Zecri
  • Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
    Patent number: 11466023
    Abstract: A combination comprising a Mcl-1 inhibitor and a second anticancer agent, wherein the second anticancer agent is selected from anthracyclines, cytarabine and hypomethylating agents, and compositions and uses thereof.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 11, 2022
    Assignees: LES LABORATOIRES SERVIER, NOVARTIS AG
    Inventors: Andrew Wei, Donia Moujalled, Giovanna Pomilio, Olivier Geneste, Ana Leticia Maragno
  • Compositions and methods for the treatment of hemoglobinopathies
    Patent number: 11466271
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: October 11, 2022
    Assignees: Novartis AG
    Inventors: Craig Stephen Mickanin, Christian Schmedt, Jennifer Snead, Susan Stevenson, Yi Yang
  • Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
    Patent number: 11459390
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 4, 2022
    Assignees: Novartis AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors
    Patent number: 11458138
    Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: October 4, 2022
    Assignee: Novartis AG
    Inventors: Dirk Behnke, Frada Berenshteyn, Xueshi Hao, Timothy Hoffman, Qihui Jin, Arnaud Lacoste, Cameron Lee, Jun Liu, Yahu Liu, Juergen Klaus Maibaum, Tingting Mo, Jianfeng Pan, Xin Qu, Jan Tchorz, Yun Feng Xie, Shanshan Yan, Yefen Zou
  • Heteroaryl butanoic acid derivatives
    Patent number: 11453651
    Abstract: The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: September 27, 2022
    Assignee: Novartis AG
    Inventors: Birgit Bollbuck, Christian Markert, Wolfgang Miltz, Till Roehn
  • Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Ca1.2 activators
    Patent number: 11453679
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: September 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Thomas Charles Caya, James Neef, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • Tricyclic compounds useful to treat orthomyxovirus infections
    Patent number: 11453677
    Abstract: The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: (I) and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions to treat viral infections.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: September 27, 2022
    Assignee: Novartis AG
    Inventors: Rama Jain, Dennis Christofer Koester, James R. Manning, James Clifford Sutton, Benjamin Robert Taft, Lifeng Wan, Qian Zhao
  • Immunomodulation by IAP Inhibitors
    Publication number: 20220296581
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Application
    Filed: June 6, 2022
    Publication date: September 22, 2022
    Applicants: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh ZAWEL, Christopher S. STRAUB, Brant G. FIRESTONE, Glenn DRANOFF, Michael DOUGAN
  • Compounds and compositions for treating conditions associated with NLRP activity
    Patent number: 11447460
    Abstract: In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 20, 2022
    Assignee: Novartis AG
    Inventors: Gary Glick, Shomir Ghosh, William R. Roush, Dong-Ming Shen
  • Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
    Patent number: 11434200
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: September 6, 2022
    Assignee: Novartis AG
    Inventors: Lianfeng Huang, Daozhong Zou
  • Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
    Patent number: 11434269
    Abstract: The present invention relates methods of treatment using BMP6 antagonists.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: September 6, 2022
    Assignee: Novartis AG
    Inventors: Feng Cong, William Dietrich, Nathalie George, Dong Liu, Asher Schachter, Aditi Soni, Jing Zhou
  • Process and intermediates
    Patent number: 11434192
    Abstract: The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril. It further relates to new intermediate compounds and their use for said new chemical synthesis route.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: September 6, 2022
    Assignee: Novartis AG
    Inventors: Florian Karl Kleinbeck-Riniker, Benjamin Martin, Gerhard Penn, Francesco Venturoni, Thierry Schlama, Thomas Ruch, Thomas Allmendinger, Bernhard Wietfeld, Paolo Filipponi
  • Polyomavirus neutralizing antibodies
    Patent number: 11433132
    Abstract: The present invention relates to anti-polyomavirus antibodies, antibody fragments, and their uses for the prevention and treatment of BK or JC virus infection and associated diseases.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: September 6, 2022
    Assignee: Novartis AG
    Inventors: Johanna Abend, Vanessa Cornacchione, John Michael Lindner, Elisabetta Traggiai
  • 1,2,4-oxadiazole derivatives as liver X receptor agonists
    Patent number: 11427586
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: August 30, 2022
    Assignee: NOVARTIS AG
    Inventors: Kelly D. Boss, Yi Fan, Alec Nathanson Flyer, Declan Hardy, Zhihong Huang, Kathryn Taylor Linkens, Jon Christopher Loren, Fupeng Ma, Valentina Molteni, Duncan Shaw, Jeffrey Smith, Catherine Fooks Solovay
  • Substituted bisphenyl butanoic ester derivatives as NEP inhibitors
    Patent number: 11426375
    Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: August 30, 2022
    Assignee: Novartis AG
    Inventors: Yongshuai Chai, Sven Erik Godtfredsen, Mark Kagan, Yugang Liu, Mahavir Prashad, Zhaoyin Wang, Saijie Zhu